Q2 2026 featured strong acute care volume rebound, stable behavioral health trends, and disciplined expense management. Updated 2026 guidance reflects 7% revenue growth and 3% EBITDA less NCI growth, with continued capital deployment in share repurchases and capacity expansion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.